Antibe Therapeutics (TSX:ATE) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Antibe Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Antibe Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Antibe Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Antibe Therapeutics's Cash-to-Debt or its related term are showing as below:

TSX:ATE' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.11 Med: 220.76 Max: No Debt
Current: No Debt

During the past 12 years, Antibe Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.11. And the median was 220.76.

TSX:ATE's Cash-to-Debt is ranked better than
99.74% of 1541 companies
in the Biotechnology industry
Industry Median: 6.49 vs TSX:ATE: No Debt

Antibe Therapeutics Cash-to-Debt Historical Data

The historical data trend for Antibe Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Antibe Therapeutics Cash-to-Debt Chart

Antibe Therapeutics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Cash-to-Debt

Get a 7-Day Free Trial

2.90

2.59

302.51

No Debt

Antibe Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Antibe Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Antibe Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Antibe Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antibe Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Antibe Therapeutics's Cash-to-Debt falls into.

Antibe Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Antibe Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Antibe Therapeutics had no debt ⁽¹⁾.

Antibe Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Antibe Therapeutics had no debt ⁽¹⁾.

Antibe Therapeutics (TSX:ATE) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Antibe Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Antibe Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Antibe Therapeutics (TSX:ATE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antibe Therapeutics Inc (TSX:ATE) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

ATBPF:USA

Address

15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2

Website

https://www.antibethera.com

Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.

Antibe Therapeutics (TSX:ATE) Headlines

No Headlines

Antibe Therapeutics (TSX:ATE) Cash-to-Debt : No Debt (1) (As of Dec. 2023)